Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Support
This activity is supported by educational grants from Astellas; Exelixis, Inc.; Genomic Health, Inc.; Merck & Co., Inc.; Pfizer Inc.; Sanofi Genzyme; and Seattle Genetics, Inc.
Community Practice Connections™ New York GU™: 13th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Release Date: May 29, 2020
Expiration Date: May 29, 2021
Activity Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of prostate cancer and urothelial carcinoma. Diagnostic tools used in prostate cancer and current and emerging treatment strategies in prostate and urothelial cancer will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.
Acknowledgement of Support
This activity is supported by educational grants from Astellas; AstraZeneca; Exelixis, Inc.; Genomic Health, Inc.; Merck & Co., Inc.; Pfizer Inc.; Sanofi Genzyme; and Seattle Genetics, Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment of patients with genitourinary (GU) malignancies. Urologists, fellows, nurse practitioners, nurses, physician assistants, pharmacists, investigators, nuclear medicine physicians, and other health care professionals interested in the treatment of GU malignancies may also participate.
Learning Objectives
Upon successful completion of this educational activity, you should be better prepared to:
- Outline the molecular pathology of GU tumors and current and emerging diagnostic concepts in GU cancers
- Describe current approaches and practice-changing clinical evidence for the management of patients with GU malignancies across multiple lines of care
- Explain strategies for monitoring, recognizing, and mitigating treatment-related toxicities associated with therapies used for GU cancers
- Determine how recent landmark findings from trials conducted among patients with GU malignancies can be placed in the context of evolving treatment paradigms in urology and medical oncology practices
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Faculty
The Bernard W. Godwin, Jr. Professor of Prostate Cancer
Chairman, Department of Urology
Associate Director, Jefferson Kimmel Cancer Center
Clinical Director, Jefferson Kimmel Cancer Center Network
Thomas Jefferson University Hospital
Philadelphia, PA
Disclosures: Consultant: Astellas Pharma Inc, MDxHealth SA, Janssen Pharmaceuticals Inc, Merck & Co Inc, Pfizer Inc.
Professor of Medicine (Medical Oncology) and Urology
Director, Prostate and GU Medical Oncology
Director, Prostate Cancer Translational Research Group
Yale Cancer Center
New Haven, CT
Disclosures: Grant Research Support: Advanced Accelerator Applications, Astellas Pharma US, Inc, AstraZeneca, Bayer AG, Bristol Myers Squibb Company, Clovis Oncology, Eli Lilly and Co, Endocyte, Genentech Inc, Innocrin Pharmaceuticals Inc, MedImmune, Merck & Co, Inc, Novartis AG, Pfizer Inc, Progenics Pharmaceuticals Inc, F. Hoffmann-La Roche Ltd, Sanofi-Aventis U.S. LLC, Seattle Genetics Inc; Consultant: Ada Cap (Advanced Accelerator Applications), Amgen Inc, Astellas Pharma US Inc, AstraZeneca, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Company, Clovis Oncology, Eli Lilly and Co, Exelixis Inc, Incyte, Janssen Pharmaceuticals Inc, Pfizer Inc, Pharmacyclics LLC, F. Hoffmann-La Roche Ltd, Seattle Genetics Inc, UroGen Pharma Inc.
Attending Physician Genitourinary Oncology Service
Sidney Kimmel Center for Prostate and Urologic Cancers
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medicine
New York, NY
Disclosures: Grant Research Support: Sanofi-Aventis U.S. LLC; Consultant: Amgen Inc, TRM Oncology, Bayer AG.
The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
